查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
原发性胆汁性胆管炎治疗药物市场：依药物类型、通路划分：2023-2032年全球机会分析与产业预测
市场调查报告书
商品编码
1344488

原发性胆汁性胆管炎治疗药物市场：依药物类型、通路划分：2023-2032年全球机会分析与产业预测

Primary Biliary Cholangitis Therapeutics Market By Drug type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 229 Pages | 商品交期: 2-3个工作天内

价格

2022年原发性胆汁性胆管炎治疗药物市值为6.8395亿美元，预计到2032年将达到14亿美元，2023年至2032年的复合年增长率为7.1%。

COVID-19 大流行扰乱了全球供应链，包括药品製造和分销。 生产设施的流动限制、封锁和劳动力减少导致原发性胆汁性胆管炎 (PBC) 治疗药物的生产和销售延误。 因此，COVID-19的爆发对原发性胆汁性胆管炎治疗药物市场产生了负面影响。

原发性胆汁性胆管炎治疗市场-IMG1

亚太地区原发性胆汁性胆管炎病例数量的增加推动了原发性胆汁性胆管炎治疗药物的市场份额不断增长。 例如，根据2021年1月发表的综述文章《原发性胆汁性胆管炎的当前认知》显示，日本人口中PBC的盛行率为每10万人中33.8人。 根据 Research Outreach 上的一篇文章称，截至 2020 年 5 月，日本估计有超过 37,000 人患有原发性胆汁性胆管炎 (PBC)。 原发性胆汁性胆管炎病例的增加增加了对原发性胆汁性胆管炎治疗药物的需求。

此外，製药业继续投资研发，以更好地了解 PBC 的潜在机制并开发创新疗法。 这包括探索新的药物标靶、进行临床试验和研究联合疗法。 因此，增加胆汁性胆管炎一线药物的研发将推动预测期内胆汁性胆管炎一线药物市场规模的成长。

PBC也是一种慢性疾病，需要长期治疗。 儘管有特定的治疗方法，但对更有效的治疗方法的需求仍然未得到满足，特别是对于对现有治疗没有充分反应的患者。 这增加了对创新和标靶治疗的需求，以满足原发性胆管炎未满足的医疗需求，推动胆汁性胆管炎药物的市场份额成长。

然而，对原发性胆汁性胆管炎 (PBC) 的认识不足、PBC 的早期诊断以及有限的治疗选择预计将阻碍原发性胆汁性胆管炎治疗药物市场的成长。 主要参与者更多地采用收购、产品批准和协议等关键策略以及一线胆汁性胆管炎药物的进步将促进一线胆汁性胆管炎药物行业在预测期内的增长。将为您铺平道路。

目录

第一章简介

第 2 章执行摘要

第三章市场概述

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 原发性胆汁性胆管炎患者增加
      • 加强研发力度
    • 抑制因素
      • 缺乏早期诊断且治疗选择有限
    • 机会
      • 更采用关键策略
  • 新冠肺炎 (COVID-19) 市场影响分析

第四章原发性胆汁性胆管炎治疗药物市场：依药物类型划分

  • 摘要
  • 主要治疗药物
  • 二级治疗药物

第五章原发性胆汁性胆管炎治疗药物市场：依通路划分

  • 摘要
  • 医院药房
  • 药局和零售药局
  • 网路药局

第六章原发性胆汁性胆管炎治疗药物市场：依地区划分

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 澳大利亚
    • 印度
    • 韩国
    • 其他亚太地区
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他领域

第七章竞争态势

  • 简介
  • 关键成功策略
  • 10家主要公司的产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022 年主要公司的定位

第八章公司简介

  • Intercept Pharmaceuticals, Inc.
  • Lupin
  • Zydus Lifesciences Limited
  • Sun Pharmaceutical Industries Ltd
  • Leeford Healthcare Limited
  • Alkem Laboratories Ltd.
  • AMAGEN INDIA LIFE SCIENCES
  • GENFIT
  • Ipsen Pharma
  • ABC Farmaceutici S.p.a.
Product Code: A108539

According to a new report published by Allied Market Research, titled, "Primary Biliary Cholangitis Therapeutics Market," The primary biliary cholangitis therapeutics market was valued at $683.95 million in 2022, and is estimated to reach $1.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032.

The COVID-19 pandemic caused disruptions in global supply chains, including pharmaceutical manufacturing and distribution. Restrictions on movement, lockdowns, and reduced workforce in manufacturing facilities led to delays in the production and distribution of primary biliary cholangitis (PBC) therapeutics. Therefore, the COVID-19 outbreak had a negative impact on the primary biliary cholangitis therapeutics market.

Primary Biliary Cholangitis Therapeutics Market - IMG1

Market Dynamics

The growth of the primary biliary cholangitis therapeutics market share is driven by the rise in cases of primary biliary cholangitis in Asia-Pacific. For instance, according to the review article "Current understanding of primary biliary cholangitis", published in January 2021, the point prevalence of PBC was 33.8 per 100,000 in the Japanese population. As per the Research Outreach article, in May 2020, over 37,000 people in Japan are estimated to have primary biliary cholangitis (PBC). Rise in the cases of primary biliary cholangitis has resulted in increased demand for primary biliary cholangitis therapeutics.

Furthermore, the pharmaceutical industry continues to invest in research and development efforts to better understand the underlying mechanisms of PBC and develop innovative therapies. This includes exploring new drug targets, conducting clinical trials, and investigating combination therapies. Therefore, the rise in research and development regarding primary biliary cholangitis therapeutics drives the growth of the primary biliary cholangitis therapeutics market size during the forecast period. in June 2021, HighTide Therapeutics ("HighTide"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, announced that the first patient has been dosed in Phase 2 PRONTO-PBC study of HighTide evaluating first-in-class HTD1801 in adult patients with primary biliary cholangitis (PBC).

Moreover, PBC is a chronic condition that requires long-term management. Despite the availability of certain therapies, there is still an unmet need for more effective treatments, particularly for patients who do not respond adequately to existing therapies. This drives the demand for innovative and targeted therapeutics to address the unmet medical needs in PBC. Hence, such factors drive the growth of the primary biliary cholangitis therapeutics market share.

However, lack of awareness regarding primary biliary cholangitis (PBC), early diagnosis of PBC, and limited treatment options are expected to hinder the growth of primary biliary cholangitis therapeutics market. On the contrary, an increase in the adoption of key strategies such as acquisition, product approval, and agreement by key players and advancements in primary biliary cholangitis therapeutics are expected to open new avenues for the growth of the primary biliary cholangitis therapeutics industry across the world during the forecast period.

The COVID-19 pandemic affected the primary biliary cholangitis therapeutics industry in a negative way, such as various healthcare industries were affected due to postponed of non-emergency services. The pandemic has disrupted research activities, including clinical trials, restrictions on patient recruitment and new product development. However, with relaxation in lockdowns and decline in COVID-19 cases, companies have re-started their processes to meet the demand for primary biliary cholangitis therapeutics. In addition, rise in product approvals, and increase in research and development of advanced medicine of primary biliary cholangitis therapeutics drive the growth of primary biliary cholangitis therapeutics market.

In addition, rise in awareness in pharmaceutical companies, and governments regarding supply chain hinderance of pharmaceutical products drives the growth of primary biliary cholangitis therapeutics market. For instance, government agencies in the U.S. and around the globe learned some tough lessons about the pharmaceutical supply chain after the COVID-19 pandemic landed, causing problems and highlighting weaknesses in key areas. In the session of "U.S. Government Investments in Pharmaceutical Manufacturing and Supply Chain and Future Pandemics for today" at the 2022 BIO International Conference, representatives from the U.S. health agencies shared lessons learned from COVID-19, and how government and industry have collaborated to avoid future supply chain crises. Moreover, the U.S. leaders stated that the government has learned since the beginning of the pandemic, steps taken since arrival of COVID-19, and plans the U.S. has put in place to avoid problems in the future. Thus, such trends are expected to bring stabilization in the market, and subsequently witness pre-pandemic growth rate during the forecast period.

Segmental Overview

The primary biliary cholangitis therapeutics market is segmented on the basis of drug type, distribution channel, and region. On the basis of drug type, the market is bifurcated into primary treatment and secondary treatment. The primary treatment segment is further categorized into obeticholic acid, ursodeoxycholic acid, and others (PPARα/PPARδ agonist, and ileal bile acid transport inhibitors). On the basis of distribution channel, it is segregated into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Key Benefits For Stakeholders:

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the primary biliary cholangitis therapeutics market analysis from 2022 to 2032 to identify the prevailing primary biliary cholangitis therapeutics market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the primary biliary cholangitis therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global primary biliary cholangitis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in cases of primary biliary cholangitis
      • 3.4.1.2. Rise in research and development
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of early diagnosis and limited treatment options
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in adoption of key strategies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Primary Drug
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Primary Drug Primary Biliary Cholangitis Therapeutics Market by Type
  • 4.3. Secondary Drug
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospital Pharmacies
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Drugs Stores and Retail Pharmacies
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Online Pharmacies
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Drug type
    • 6.2.3. Market size and forecast, by Distribution Channel
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Drug type
      • 6.2.4.1.3. Market size and forecast, by Distribution Channel
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Drug type
      • 6.2.4.2.3. Market size and forecast, by Distribution Channel
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Drug type
      • 6.2.4.3.3. Market size and forecast, by Distribution Channel
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Drug type
    • 6.3.3. Market size and forecast, by Distribution Channel
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Drug type
      • 6.3.4.1.3. Market size and forecast, by Distribution Channel
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Drug type
      • 6.3.4.2.3. Market size and forecast, by Distribution Channel
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Drug type
      • 6.3.4.3.3. Market size and forecast, by Distribution Channel
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Drug type
      • 6.3.4.4.3. Market size and forecast, by Distribution Channel
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Drug type
      • 6.3.4.5.3. Market size and forecast, by Distribution Channel
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Drug type
      • 6.3.4.6.3. Market size and forecast, by Distribution Channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Drug type
    • 6.4.3. Market size and forecast, by Distribution Channel
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Drug type
      • 6.4.4.1.3. Market size and forecast, by Distribution Channel
      • 6.4.4.2. China
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Drug type
      • 6.4.4.2.3. Market size and forecast, by Distribution Channel
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Drug type
      • 6.4.4.3.3. Market size and forecast, by Distribution Channel
      • 6.4.4.4. India
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Drug type
      • 6.4.4.4.3. Market size and forecast, by Distribution Channel
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Drug type
      • 6.4.4.5.3. Market size and forecast, by Distribution Channel
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Drug type
      • 6.4.4.6.3. Market size and forecast, by Distribution Channel
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Drug type
    • 6.5.3. Market size and forecast, by Distribution Channel
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Drug type
      • 6.5.4.1.3. Market size and forecast, by Distribution Channel
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Drug type
      • 6.5.4.2.3. Market size and forecast, by Distribution Channel
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Drug type
      • 6.5.4.3.3. Market size and forecast, by Distribution Channel
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Drug type
      • 6.5.4.4.3. Market size and forecast, by Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Intercept Pharmaceuticals, Inc.
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. Lupin
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. Zydus Lifesciences Limited
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. Sun Pharmaceutical Industries Ltd
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Leeford Healthcare Limited
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
  • 8.6. Alkem Laboratories Ltd.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
  • 8.7. AMAGEN INDIA LIFE SCIENCES
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
  • 8.8. GENFIT
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
    • 8.8.7. Key strategic moves and developments
  • 8.9. Ipsen Pharma
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
    • 8.9.7. Key strategic moves and developments
  • 8.10. ABC Farmaceutici S.p.a.
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 02. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR PRIMARY DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL PRIMARY DRUG PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR SECONDARY DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 06. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 13. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 14. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 15. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 16. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 22. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 27. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 29. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 37. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 40. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 42. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 44. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 53. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 55. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 57. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 59. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. INTERCEPT PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 61. INTERCEPT PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 62. INTERCEPT PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 63. INTERCEPT PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 64. INTERCEPT PHARMACEUTICALS, INC.: KEY STRATERGIES
  • TABLE 65. LUPIN: KEY EXECUTIVES
  • TABLE 66. LUPIN: COMPANY SNAPSHOT
  • TABLE 67. LUPIN: PRODUCT SEGMENTS
  • TABLE 68. LUPIN: PRODUCT PORTFOLIO
  • TABLE 69. LUPIN: KEY STRATERGIES
  • TABLE 70. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 71. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 72. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 73. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 74. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
  • TABLE 75. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 76. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 77. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
  • TABLE 78. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 79. LEEFORD HEALTHCARE LIMITED: KEY EXECUTIVES
  • TABLE 80. LEEFORD HEALTHCARE LIMITED: COMPANY SNAPSHOT
  • TABLE 81. LEEFORD HEALTHCARE LIMITED: PRODUCT SEGMENTS
  • TABLE 82. LEEFORD HEALTHCARE LIMITED: PRODUCT PORTFOLIO
  • TABLE 83. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 84. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 85. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 86. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 87. AMAGEN INDIA LIFE SCIENCES: KEY EXECUTIVES
  • TABLE 88. AMAGEN INDIA LIFE SCIENCES: COMPANY SNAPSHOT
  • TABLE 89. AMAGEN INDIA LIFE SCIENCES: PRODUCT SEGMENTS
  • TABLE 90. AMAGEN INDIA LIFE SCIENCES: PRODUCT PORTFOLIO
  • TABLE 91. GENFIT: KEY EXECUTIVES
  • TABLE 92. GENFIT: COMPANY SNAPSHOT
  • TABLE 93. GENFIT: PRODUCT SEGMENTS
  • TABLE 94. GENFIT: PRODUCT PORTFOLIO
  • TABLE 95. GENFIT: KEY STRATERGIES
  • TABLE 96. IPSEN PHARMA: KEY EXECUTIVES
  • TABLE 97. IPSEN PHARMA: COMPANY SNAPSHOT
  • TABLE 98. IPSEN PHARMA: PRODUCT SEGMENTS
  • TABLE 99. IPSEN PHARMA: PRODUCT PORTFOLIO
  • TABLE 100. IPSEN PHARMA: KEY STRATERGIES
  • TABLE 101. ABC FARMACEUTICI S.P.A.: KEY EXECUTIVES
  • TABLE 102. ABC FARMACEUTICI S.P.A.: COMPANY SNAPSHOT
  • TABLE 103. ABC FARMACEUTICI S.P.A.: PRODUCT SEGMENTS
  • TABLE 104. ABC FARMACEUTICI S.P.A.: PRODUCT PORTFOLIO
  • TABLE 105. ABC FARMACEUTICI S.P.A.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW INTENSITY OF RIVALRY
  • FIGURE 08. LOW BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET
  • FIGURE 09. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR PRIMARY DRUG, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR SECONDARY DRUG, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY REGION, 2022
  • FIGURE 17. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 18. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 19. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 20. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 40. COMPETITIVE DASHBOARD
  • FIGURE 41. COMPETITIVE HEATMAP: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET
  • FIGURE 42. TOP PLAYER POSITIONING, 2022
  • FIGURE 43. INTERCEPT PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 44. LUPIN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 46. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 47. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 48. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 49. SUN PHARMACEUTICAL INDUSTRIES LTD: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 51. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. GENFIT: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. IPSEN PHARMA: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 55. IPSEN PHARMA: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. IPSEN PHARMA: REVENUE SHARE BY REGION, 2022 (%)